|Category:||Clinical Biotech Company|
|Time:||12:30 – 12:45|
|Speaker:||Lynn Durham, CEO & Founder|
STALICLA is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders. STALICLA´s unique approach addresses a principal weakness in the drug development process for NDDs and neuropsychiatric disorders: behavior is a terrible biomarker. STALICLA is currently preparing its next stage of growth, to advance its pipelines and to scale its platform.